Stock market week-in-review for 5 large GI companies — Sept. 5-8

Here is how five major, publicly traded gastroenterology companies fared in the stock market for the week of Sept. 5 to Sept. 8, 2017.

Advertisement

Note: This data was compiled using Google Finance.

1. Allergan Pharmaceuticals

Opened: $226.78 on Sept. 5
Peaked: $234.59 on Sept. 8
Closed: $233.61 on Sept. 8
Percent change between Sept. 5 to Sept. 8: 3.01 percent

2. Exact Sciences Corp.

Opened: $41.61 on Sept. 5
Peaked: $43.27 on Sept. 7
Closed: $42.42 on Sept. 8
Percent change between Sept. 5 to Sept. 8: 1.92 percent

3. Johnson & Johnson

Opened: $130.34 on Sept. 5
Peaked: $132.49 on Sept. 7
Closed: $131.06 on Sept. 8
Percent change between Sept. 5 to Sept. 8: 0.55 percent

4. Synergy Pharmaceuticals

Opened: $3.01 on Sept. 5
Peaked: $3.11 on Sept. 5
Closed: $2.79 on Sept. 8
Percent change between Sept. 5 to Sept. 8: -7.3 percent

5. Valeant Pharmaceuticals

Opened: $13.32 on Sept. 5
Peaked: $13.56 on Sept. 8
Closed: $13.62 on Sept. 8
Percent change between Sept. 5 to Sept. 8: 2.25 percent

More articles on gastroenterology:
CapsoVision launches CapsoCloud to make CapsoCam data extraction easier — 3 key notes
GI leader to know: Dr. Marla Dubinsky of Mount Sinai Hospital
FDA grants Innovate Biopharma’s ulcerative colitis drug orphan designation — 3 insights

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.